EXKIVITY® (Mobocertinib)

The FDA on September 15, 2021, granted accelerated approval to EXKIVITY® for adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. EXKIVITY® is a product of Takeda Pharmaceuticals, Inc.